| |
Tuesday, December 3, 2024 | 11am ET / 8am PT Join us for a deep dive into the development and manufacturing of monoclonal antibodies. We’ll explore an industry case study, providing access to key findings, top strategies and solutions for enhancing productivity and efficiency in mAb production. Don’t miss out on important insights, register now.
|
|
Today’s Big NewsNov 21, 2024 |
|
Wednesday, December 4, 2024 | 11am ET / 8am PT Designing nanodevices that can change shape and function in response to molecular signals is a key objective in protein design, paving the way for the development of switchable nanomaterials, triggerable drug-delivery systems, and molecular motors. Join us for a deep dive into the recent progress in designing and characterizing a diverse range of switchable protein assemblies. Register now.
|
|
| By Fraiser Kansteiner Given president-elect Donald Trump’s focus on matters beyond healthcare and a more hands-off approach to government regulation, the life sciences realm is unlikely to face a major shakeup—at least for now—Baird’s biotech specialist Mike Perrone opined Thursday. |
|
|
|
By James Waldron Novartis had one eye on the struggles its peers have encountered in the muscular dystrophy space recently when it decided to acquire Kate Therapeutics, according to the Big Pharma’s CEO. |
By Fraiser Kansteiner While one might expect a positive readout from a biotech’s lead candidate to boost the company’s stock price, Pyxis Oncology’s shares—which have tumbled more than 40% this week—tell a different story. |
By Angus Liu A bispecific antibody has entered the HER2 fray with a differentiated profile from traditional agents and a chance to challenge AstraZeneca and Daiichi Sankyo’s star ADC Enhertu. |
|
Thursday, December 5, 2024 | 1pm ET / 10am PT Learn how to leverage comprehensive patient journeys to improve targeting, understand unmet needs, and optimize your competitive strategy with real-world evidence that sees what others can’t. Register now to gain a competitive edge by evolving beyond traditional, limited datasets and unlock a deeper understanding of patient and physician decision-making.
|
|
By Conor Hale BD’s HPV test received an FDA approval in May, alongside a test developed by Roche, that allows women to skip the traditional Pap smear exam. |
By Kevin Dunleavy Novartis has adjusted its compound annual growth rate expectation from 5%-plus to 6%-plus through 2029. The Swiss company cited the momentum of its current growth drivers, which have paved the way for a strong sales performance this year. |
By Darren Incorvaia After two and a half years at sea, Flagship Pioneering-backed cell signaling company Sonata Therapeutics is whittling down its crew by 20 employees, a company spokesperson confirmed to Fierce Biotech. |
By Conor Hale BlueSeal scanners only require 7 liters of helium during their manufacture, while previous imagers may need as much as 1,500 over their lifetime. |
By Zoey Becker The Johns Hopkins surgeon was an outspoken critic of vaccine mandates during the COVID pandemic, favoring natural and herd immunity instead. Bloomberg and Reuters, citing sources, reported on the potential selection. |
By James Waldron Genmab's Anthony Pagano sat down with Fierce Biotech at the Jefferies conference in London to talk M&A, asset ownership and whether the company will become an autoimmune disease player. |
By Gabrielle Masson In a few weeks, Howard Chang, M.D., Ph.D., will join Amgen, filling the roles both of senior vice president of research and chief scientific officer. |
Fierce podcastsDon’t miss an episode |
| | This week on "Podnosis," we explore the rise of voice phishing, or vishing, where cybercriminals use AI to mimic voices and breach sensitive healthcare data. |
|
|---|
|
|
|
Tuesday, December 10, 2024 | 12pm ET / 9am PT Mammalian synthetic biology has shown that key principles of biological regulation can be rewritten to control gene expression and produce complex, cellular behaviors. Recently, these core principles have now been applied at the protein level. Join us to learn about these latest approaches, and what the mean for cancer biology, immunology, and neuroscience. Sign up now!
|
|
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| WhitepaperThis e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
| WhitepaperUnlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
